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ABSTRACT
Introduction: The inappropriate use of antipsychotics
in people with dementia for behaviour that challenges
is associated with an estimated 1800 deaths annually.
However, solely focusing on antipsychotics may
transfer prescribing to other equally dangerous
psychotropics. Little is known about the role of
pharmacists in the management of psychotropics used
to treat behaviours that challenge. This research aims
to determine whether it is feasible to implement and
measure the effectiveness of a combined pharmacy–
health psychology intervention incorporating a
medication review and staff training package to limit
the prescription of psychotropics to manage behaviour
that challenges in care home residents with dementia.
Methods/analysis: 6 care homes within the West
Midlands will be recruited. People with dementia
receiving medication for behaviour that challenges, or
their personal consultee, will be approached regarding
participation. Medication used to treat behaviour that
challenges will be reviewed by the pharmacist, in
collaboration with the general practitioner (GP), person
with dementia and carer. The behavioural intervention
consists of a training package for care home staff and
GPs promoting person-centred care and treating
behaviours that challenge as an expression of unmet
need. The primary outcome measure is the
Neuropsychiatric Inventory-Nursing Home version
(NPI-NH). Other outcomes include quality of life
(EQ-5D and DEMQoL), cognition (sMMSE), health
economic (CSRI) and prescribed medication including
whether recommendations were implemented.
Outcome data will be collected at 6 weeks, and 3 and
6 months. Pretraining and post-training interviews will
explore stakeholders’ expectations and experiences of
the intervention. Data will be used to estimate the
sample size for a definitive study.
Ethics/dissemination: The project has received a
favourable opinion from the East Midlands REC
(15/EM/3014). If potential participants lack capacity,
a personal consultee will be consulted regarding
participation in line with the Mental Capacity Act.
Results will be published in peer-reviewed journals and
presented at conferences.
INTRODUCTION
Numerous reports have highlighted that care
home residents with dementia receive sub-
standard care with a key concern being the
appropriate treatment of behaviour that
challenges.1 2 Behaviour that challenges is
deﬁned as ‘any behaviour considered anti-
social within the care environment or
deemed dangerous to the person with
dementia, their fellow residents, and staff’.3
Behaviour that challenges is used inter-
changeably with the label, behavioural and
psychological symptoms of dementia
(BPSD), and such behaviours occur in
approximately 70% of residents and are trad-
itionally treated with psychotropics, particu-
larly antipsychotics.2 4 5
The number of people with dementia pre-
scribed psychotropic medication is unknown.
The National Dementia Strategy estimated
that 180 000 people with dementia receive
antipsychotics, yet only 20% of those
Strengths and limitations of this study
▪ This is the first study to assess the feasibility of
an interdisciplinary intervention involving a medi-
cation review and a behavioural intervention.
▪ The study uses a mixed-methods approach and
will also collect health economic data.
▪ The feasibility study is conducted in a single
location; a future planned cluster randomised
controlled trial (RCT) will be extended to cover
other areas.
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prescribed are likely to beneﬁt and the usage of such
antipsychotics is implicated in the death of 1800 people
with dementia annually.2 6 The Department of Health
targeted a two-thirds reduction in such usage in 2009.2 6
However, simply targeting antipsychotics may increase
the prescribing of other psychotropics such as loraze-
pam, which are generally ineffective and associated with
serious side effects including pneumonia, fractures, falls
and confusion.4 7–22 Lorazepam usage was not included
in the 2012 national audit of the treatment of behaviour
that challenges (BPSD).23 Thus, in line with recommen-
dations from a recent Cochrane review, future research
should test interventions to limit the use of all psychotro-
pics and not just focus on antipsychotics.24
The National Dementia Strategy and guidance from
the Royal Pharmaceutical Society highlighted the role of
pharmacist-led medication review in ensuring the appro-
priate treatment of BPSD.2 6 25 Successful pharmacy
approaches to medication review have adopted a collab-
orative approach and used highly skilled clinical phar-
macists; therefore, any effective intervention is likely to
require the input of specialists, working collaboratively
with general practitioners (GPs), community pharma-
cists, patients and carers.26–32 While recent White Papers
highlight an outreach role for specialist pharmacists,
there is a lack of data on the efﬁcacy and cost-
effectiveness of such an approach.1 24 33–35 Furthermore,
the likely impact of a specialist medication review is
unknown. Reduced psychotropics may result in people
with dementia exhibiting more behaviour that chal-
lenges, thus requiring changes in their care. As a result,
this study proposes to combine the pharmacy-based
medication review with a health psychology-informed
training package for care staff and GPs. This study will
determine the ﬁt to context, the acceptability and feasi-
bility of a combined pharmacy–health psychology inter-
vention to reduce psychotropics while managing
behaviours that challenge effectively.
This research aims to determine whether it is feasible
to implement and measure the effectiveness of a com-
bined pharmacy–health psychology intervention incorp-
orating a medication review and staff training package to
limit the prescription of psychotropics to manage behav-
iour that challenges in residential and nursing home
residents.
The objectives are:
1. To deliver and evaluate a full medication review to
reduce the prescription of psychotropics for the treat-
ment of behaviour that challenges.
2. To deliver and evaluate a training package for care
home staff and GPs to provide appropriate care for
people with dementia exhibiting behaviour that
challenges.
3. To test the feasibility of proposed methods including
identiﬁcation of participants, recruitment and reten-
tion rates (homes and participants), acceptability and
ﬁdelity of the intervention, sample size, follow-up
rates and outcome measurement tools.
4. To inform the development of a deﬁnitive cluster
randomised controlled trial (CRCT).
METHODS AND ANALYSIS
Details of the methods are described below (informed
by SPIRIT36 and TIDieR37 guidance). The full protocol
is available on the project website (http://www.aston.ac.
uk/medrev/).
Participants and recruitment
We aim to recruit three residential care homes and
three nursing homes. Recruitment will be informed by
Enabling Research in Care Homes (ENRICH).38 All care
homes that include residents with dementia in the West
Midlands (within 6 miles of Birmingham) with at least
40 residents will be identiﬁed from the Care Quality
Commission (CQC) website and invited to participate
via a letter from the chief investigator. Expressions of
interest will be followed up in face-to-face meetings by
the chief investigator and project manager.
On the basis of the National Dementia Strategy and
previous work, we expect at least 30% of residents to
meet the inclusion criteria: giving 18+ potential partici-
pants per home.2 6 39 40 Recruitment and attrition rates
will be monitored to inform the recruitment strategy
and sample size for the CRCT; the target number of par-
ticipants for this feasibility study is 45.
Participant inclusion criteria
1. Receiving medication (including, but not limited to,
medicines in British National Formulary (BNF) sec-
tions 4.1/4.2/4.3/4.11) to treat behaviour that
challenges.
2. Resident within a long-term care facility.
3. Registered with a West Midlands GP (who has also
agreed to participate).
4. Dementia conﬁrmed (dementia register, documenta-
tion of relevant read codes, conﬁrmation of diagnosis
via communication from old age psychiatry, memory
clinic or clinical psychologist).
5. Patient, or personal consultee, willing to provide
consent/assent.
6. A proxy informant (key worker or staff member with
close working relationship) who can clearly commu-
nicate in English available.
Participant exclusion criteria
1. Patient, or personal consultee, unable or unwilling to
provide consent or lacks necessary English-language
skills.
2. On palliative care register, or has pathology requiring
complex specialist medication.
3. Risk of harm in line with Alzheimer’s Society guide-
lines (guidelines published in 2011, currently being
updated and therefore not available).
4. Severe mental illness (eg, schizophrenia) where
psychotropic treatment should be continued.
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Study design
This feasibility study is set within the Medical Research
Council (MRC) framework for developing complex
interventions.41 The behavourial intervention will be
delivered ﬁrst so that care staff have an understanding of
challenging behaviour potentially as communication
of an unmet need in advance of any changes in
medication.
Health psychology-informed behavioural intervention
The health psychology-informed component of the
intervention constitutes a behavioural intervention to be
delivered in the form of a training package (table 1).
The development of this training package has been
informed by elicitation research involving a review of the
evidence base and good practice guidelines for man-
aging behaviour that challenges, and in-depth interviews
with stakeholder groups. It has been developed using
the Capability, Opportunity, Motivation and Behaviour
(COM-B) model for the development of behavioural
interventions in healthcare.42 This model helped to
isolate the target behaviours and identify techniques for
changing those behaviours (a publication detailing the
development of the health psychology-informed behav-
ioural intervention is in progress). We will collect data
on the proportion of staff attending training sessions at
each home. Basic demographic information on those
receiving the intervention (care staff and GPs) will also
be collected.
Pharmacy-based medication review
The protocol for the medication review has been devel-
oped and has undergone initial piloting.39 40 An experi-
enced specialist dementia care clinical pharmacist will
conduct the medication review. Prior to the review, the
pharmacist will discuss the patients’ medication history,
rationale for the current regimen and any potential
issues with the GP and, if necessary, other clinical specia-
lists such as community psychiatric nurses (CPNs). The
review will proceed in line with Alzheimer’s Society
guidelines (guidelines published in 2011, currently
being updated and therefore not available). It will be a
process involving dialogue between the pharmacist, GP,
carer and patient (with active involvement where pos-
sible; table 2 for outline).
Outcome measures
Primary
The Neuropsychiatric Inventory (NPI) is a caregiver-
administered questionnaire that assesses 12 key neuro-
psychiatric symptoms.43 A speciﬁc nursing home version
(Neuropsychiatric Inventory-Nursing Home version
(NPI-NH)) designed for interviewing professional care
staff will be used.44 45 The decrease in the NPI-NH
change score between baseline and 3 months will be the
primary measure; it will also be collected at 6 weeks and
6 months. A decrease in four points, or more, will be
considered a clinically meaningful change in the
NPI-NH.44
Table 1 Outline of training packages
Training package for care home staff: The training package will provide care home staff with the knowledge to understand that
behaviours that challenge may be an expression of unmet need.
Within this, the intervention aims
to provide care home staff with
the skills and resources to
▸ Investigate what the unmet need might be
▸ Get to know the person with dementia as an individual to help manage their behaviour
▸ Think creatively about how to prevent challenging behaviours by making sure
individuals’ needs are met
▸ Understand that behaviours that challenge are not ‘bad behaviour’.
Mode of delivery The intervention will be delivered in brief face-to-face training programmes for all care
home staff, including managers, at the care home. The training will be delivered at a time
convenient for the care staff.
Content Up to 2–3 h training package including handouts, worksheets, aide-mémoires (for
handover, in residents’ rooms, communal areas), scenario-based role plays and interactive
activities. Manuals will be provided to be kept in the care home for staff access.
Facilitation The intervention training will be delivered by specialist health psychologists on the project
team with support from community psychiatric nurses (CPNs) within the participating trust.
Champions within homes will be identified to help maintain the key message (challenging
behaviour may be an expression of unmet need).
Monitoring and evaluation The researcher will be in regular contact with the care home managers and champions
and will carry out regular visits. This will ensure staff are maintaining the key lessons of
the intervention and that all materials (manuals, aide-mémoires, etc are still readily
available on site) are used throughout the study period. The researcher will use field notes
to support the evaluation of the intervention.
Training package for general practitioners (GPs)
GPs will be given access to the care home staff training package. In addition, a short training session (face-to-face or online)
will be provided which will include additional information about specific drugs, potential side effects, interactions between
antipsychotics and between antipsychotics and medications for other long-term conditions, as well as information relating to
advocacy skills and phrases to help GPs convey the key messages of the intervention to care home staff and families.
Maidment ID, et al. BMJ Open 2016;6:e010279. doi:10.1136/bmjopen-2015-010279 3
Open Access
group.bmj.com on March 29, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Secondary
Collected at baseline (before the medication review),
6 weeks and 3 and 6 months (unless stated):
1. Quality of Life (QoL), DEMQoL and EuroQoL
EQ-5D (proxy versions).46–48 Participants may not be
able to respond and to reduce any ‘proxy effect’ care-
givers will be requested to respond ‘as if’ they were
the person with dementia.46 (EQ-5D only collected at
baseline, 3 and 6 months; DEMQoL collected at all
time points.)
2. Cognitive test: standardised Mini-Mental State
Examination (sMMSE).49 50 The sMMSE is based on
original Mini-Mental State Examination (MMSE), the
most widely used cognitive test worldwide with good
psychometric properties.51 52 The sMMSE provides
explicit guidelines for administration and scoring to
improve reliability. Both the MMSE and the sMMSE
have been shown to be sensitive to the effects of
medication on cognition in previous trials including
a trial led by a coapplicant (CF) in the same popula-
tion.53–55 (sMMSE only collected at baseline, 6 weeks
and 3 months.)
3. All prescribed medication.
4. Costs: a modiﬁed version of the Client Service
Receipt Inventory (CSRI) will be used to monitor
levels of resource use associated with the medication
review (including preparation and recommenda-
tions) and the use of other National Health Service
(NHS) and Personal Social Service (PSS) resource
items—for example, medication utilisation, GP ser-
vices and hospital visits/admissions.56 57 This will be
completed by proxy. (Only collected at baseline, 3
and 6 months).
Qualitative evaluation
The qualitative evaluation of the combined pharmacy–
health psychology intervention will have two functions:
to explore the context, acceptability, ﬁdelity of the inter-
vention and feasibility of the medication review if tested
in a deﬁnitive CRCT and to examine the change process
in care homes and evaluate the quality and acceptability
of the training package for care staff and GPs.
Preintervention and postintervention interviews
Individual semistructured interviews will be conducted
with key stakeholders (care staff (n=12), home managers
(n=6) and GPs (n=3)). Interviews have been chosen
because they give participants the opportunity to lead
the discussion,58 59 be conﬁdent that data will be kept
conﬁdential and because questions can be tailored
through active listening so that the interviewer can gain
a detailed understanding of the participants’ subjective
experience within their role in relation to the interven-
tion and their speciﬁc context.
Interviews will be conducted before the medication
review is implemented and before the training package
is delivered. Questions will focus on perceptions of the
medication review and expectations related to challen-
ging behaviour following reductions in psychotropics.
Interviews will be repeated with the same staff (or repre-
sentatives) following the intervention which will explore
stakeholders’ perceptions of the medication review and
training package. It will examine the change process in
detail.
The goal of the intervention is to support through
medication review and training a staged withdrawal of
psychotropics, if indicated. However, we cannot predict
what will be the most important implications for individ-
ual care homes. A key objective of the interviews will be
to gather perceptions and opinions from people in dif-
ferent positions to assess the key facilitators and barriers
for residents and for care staff managing the impact of
the withdrawal of psychotropics, and for management
staff who need to oversee the process and ensure staff
are supported to manage the process.
Opinions will be sought from GPs about the interven-
tion and what support or systems they feel need to be
put in place for it to be successful. Furthermore, the
triggers for prescribing psychotropics will need to be
identiﬁed; the prescription may be something which
family members or carers feel is necessary, or GPs may
initiate it.
Analysis
Statistics
The analysis will be primarily descriptive and consider
recruitment and retention of homes and individuals.
The number of patients screened for eligibility within
each home, the number of patients meeting study inclu-
sion criteria and the number of patients who consent to
participate will be collected. For homes, the number
approached and the number consenting will be
Table 2 Outline of the pharmacy-based medication
review
1 The primary focus of the intervention is to review
psychotropics for behaviours that challenge; the
pharmacist will also review all medication as per
routine clinical care.
2 Establish a therapeutic alliance with the person with
dementia and/or personal consultee.
3 Consult clinical records for existing diseases and
current medications.
4 Collect information about the patient which may affect
their disease progression or treatment.
5 Collect information about any challenging behaviour
exhibited by the person with dementia.
6 Assess whether any other current medication may
contribute to the challenging behaviour.
7 Review the prescription of medication including
treatments used to treat psychotropic-induced adverse
events.
8 Provide a verbal summary and written record of the
medication review, including recommendations for
medication and managing adverse events, to care staff,
GP, person with dementia/personal consultee and
dispensing community pharmacy, as appropriate.
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calculated together with variables characterising the
homes (eg, size, type, number of staff). These data will
provide information on the potential ﬂow of participants
and will be used to estimate the numbers that need to
be approached in a deﬁnitive trial to meet the required
sample size. Information will also be collected on the
interventions implemented, the number of patients
completing follow-up and the completeness of data at
each time point. Demographic information and baseline
data will be summarised using means/SDs and/or
medians/IQRs as appropriate to assess the patients
entered into the study and to allow estimation of the
sample size for a deﬁnitive trial.
Cost-effectiveness
The main purpose is to inform how data oncosts and
effects would be collected within a deﬁnitive study. We
will estimate completion rates and seek to identify big
cost drivers in order to inform this decision. Levels of
resource use associated with the medication review
(including preparation and recommendations) will be
recorded by those who deliver it. Additionally, we will
use a modiﬁed version of the CRSI (to be completed by
proxy) to monitor other NHS and PSS resource items—
for example, medication utilisation, GP services and hos-
pital visits/admissions.57 Appropriate unit costs will be
attached to all items of resource use, including medica-
tion costs, to estimate the mean overall cost.60 EQ-5D48
and DEMQoL46 47 data will be used to estimate the
quality-adjusted life year (QALY) gain,48 61 both will be
completed via proxy.
Qualitative
Interview data will be analysed using framework ana-
lysis.58 This is a method led by thematic analysis in the
ﬁrst instance which then lends itself particularly well to
comparing between groups and against pre-existing evi-
dence.59 Initially, thematic analysis will be conducted on
each individual interview to generate a set of themes.
Accounts will be collated by stakeholder group and a
cross-comparison analysis undertaken for each one. A
framework (or matrix) of themes by group will be
created to facilitate this cross-group analysis. At this
point, we will assess the themes generated inductively
against reviews of literature, best practice guidance and
health psychology theory and incorporate anything not
already identiﬁed in the interview data. Analysis of
results will therefore combine empirical data with the
evidence base and health psychology theory and will be
used to evaluate the appropriateness and effectiveness of
the intervention—both the medication review and the
training package for staff.
ETHICS AND DISSEMINATION
The project has received a favourable opinion from East
Midlands (Nottingham 1) Research Ethics Committee
(REC; reference 15/EM/3014). The most signiﬁcant
ethical issue associated with this study is the inclusion of
people with dementia, some of whom may not have the
capacity to give informed consent. Study recruitment
and delivery will be informed by ENRICH and sup-
ported by staff with training and experience of working
in this setting and with the study population. We will
manage the study in accordance with good clinical prac-
tice and put in place the following speciﬁc two-stage
process in relation to consent.
In stage 1, a key worker, on the researcher’s behalf,
will give eligible residents who meet the study inclusion
criteria (which includes the ability to read and under-
stand written information) the study participant infor-
mation sheet; this will also be posted to the personal
consultee. Personal consultees who have not responded
to the letter will be contacted after 2 weeks to follow-up
the invitation to participate in the study. Residents/per-
sonal consultees who wish to consider participating in
the study will then be introduced to the research team
who will provide any additional information that is
required.
In stage 2, if consent is obtained at stage 1, fully
trained research assistants (RAs) will attempt to seek
consent from residents to participate in the study.
Capacity will be assessed using the Mental Capacity Act
(2005)62 63 and local NHS Trust (Birmingham and
Solihull Mental Health NHS Foundation Trust) guide-
lines. All practical steps to maximise the individual’s
ability to provide informed consent will be taken. When
an individual has sufﬁcient capacity, written informed
consent will be obtained. Sufﬁcient time will be taken to
explain what participation entails, including any poten-
tial hazards and/or discomfort and the participant’s
right to withdraw without providing any explanation for
doing so.64 65
If capacity is lacking, a personal consultee will be
informed about the study and consulted for advice on
whether or not the potential participant would want to
participate.62 63 The Declaration of Helsinki, which
states that assent is required, and British Psychological
Society guidelines will also be followed. All consenting
residents and their carers will be informed that they can
withdraw from the study at any time. Consent will be
conﬁrmed at each interaction with participants.
There is a potential risk of harm if psychotropic medi-
cation is withdrawn and the other support mechanisms
that are put in place do not effectively manage any
behaviour that challenges exhibited by participants. To
counter this risk, we will exclude potential participants
where a risk of harm to themselves or others has been
identiﬁed; this is in line with widely used guidelines from
the Alzheimer’s Society. Furthermore, we are putting
training in place to help care staff manage any behaviour
that challenges. Finally, risk of harm will also be mini-
mised by active involvement of the GP and care staff in
the medication review, if indicated the decision to with-
draw the medication being determined by the GP, and as
appropriate medication will be reintroduced by the GP.
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The main focus for dissemination would be after any
future deﬁnitive trial. However, we plan to publish the
results from this feasibility study and the embedded
qualitative study in peer-reviewed international journals.
Our results will also be presented at international
conferences.
DISCUSSION
Any intervention to reduce the use of antipsychotics in
people with dementia must be sustainable and not lead
to an increase in the use of equally dangerous other psy-
chotropics, such as lorazepam. We propose that a full
clinical medication review by a specialist dementia care
clinical pharmacist, with the GP, combined with a behav-
ioural intervention for care staff and GPs, may be able to
sustainably limit the use of all psychotropics in people
with dementia. This study will establish whether it is feas-
ible to implement and measure the effectiveness of a
combined pharmacy–health psychology-informed inter-
vention. The results from the outcome measures and
qualitative evaluation will inform a deﬁnitive multicentre
CRCT. It will do this by providing data on participant
identiﬁcation, recruitment and retention rates, accept-
ability of the intervention, the necessary sample size and
outcome measurement tools. If we can demonstrate that
the intervention is effective, this will have considerable
implications for practice, in particular how to embed a
change in prescribing practice for behaviour that chal-
lenges and also the way that the specialist secondary
care workforce is deployed.
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